Drugs / Len+DEB-TACE
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06492395 | Aug 2024 → Jul 2026 overdue | hepatocellular carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Len+DEB-TACE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06492395 ↗ |
| Route | Oral | “P.O. qd” NCT06492395 ↗ |